“…Thrombin time is prolonged by: decreased fibrinogen levels; abnormal function of fibrinogen; the presence of direct thrombin inhibitors, such as dabigatran, bivalirudin or argatroban; the presence of unfractionated heparin; the presence of aprotinin; and the presence of fibrinogen/fibrin degradation products and/or increased fibrinolysis (for example, due to thrombolytic therapy) . D‐dimer is a very sensitive marker for the activation of coagulation . In DIC, fibrin degradation products, such as D‐dimer, can be used to confirm or refute a tentative diagnosis, estimate the potential risk for patients with existing DIC, and monitor an initiated therapy .…”